Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.51 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464373 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL12191970 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489111 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL5311408 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489112 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL6685329 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL24696627 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13818478 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13818477 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13713744 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3980052-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210198339-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198339-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | US | disclosed |
| EP-1562654-A1 | MEDICAL DEVICES INCORPORATING DEUTERATED RAPAMYCIN FOR CONTROLLED DELIVERY THEREOF | Isotechnika International Inc. (BB) | 2005-08-17 | — | — | EP | disclosed |
| US-6884429-B2 | Medical devices incorporating deuterated rapamycin for controlled delivery thereof | ISOTECHNIKA INTERNATIONAL INC. (BB) | 2005-04-26 | — | — | US | disclosed |
| US-20040198762-A1 | Deuterated rapamycin compounds, method and uses thereof | ISOTECHNIKA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
| WO-2004045668-A1 | MEDICAL DEVICES INCORPORATING DEUTERATED RAPAMYCIN FOR CONTROLLED DELIVERY THEREOF | ISOTECHNIKA INTERNATIONAL INC. (BB) | 2004-06-03 | — | — | WO | disclosed |
| US-6710053-B2 | IMMUNOSUPPRESSANT; AUTOIMMUNE DISEASE; ANTICANCER, ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; WATER SOLUBILITY | ISOTECHNIKA INTERNATIONAL INC. (BB) | 2004-03-23 | — | — | US | disclosed |
| US-20030139440-A1 | Deuterated rapamycin compounds, method and uses thereof | ISOTECHNIKA INC. (CA) | 2003-07-24 | — | — | US | disclosed |
| US-20030130206-A1 | Medical devices incorporating deuterated rapamycin for controlled delivery thereof | ISOTECHNIKA INC. (CA) | 2003-07-10 | — | — | US | disclosed |
| US-6503921-B2 | For treatment of transplantation rejection, graft vs host disease, autoimmune diseases, diseases of inflammation leukemia/lymphoma, solid tumors, fungal infections and hyperproliferative vascular disorders; pharmacokinetics | ISOTECHNIKA, INC. (CA) | 2003-01-07 | — | — | US | disclosed |
| US-20020028827-A1 | Deuterated rapamycin compounds, method and uses thereof | ISOTECHNIKA, INC. (CA) | 2002-03-07 | — | — | US | disclosed |
| US-6342507-B1 | Deuterated rapamycin compounds, method and uses thereof | ISOTECHNIKA, INC. (CA) | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130206-A1 | Medical devices incorporating deuterated rapamycin for controlled delivery thereof | RICTOR, MTOR, MLST8 | IGF2R 536/4885GAA 899/4885LGALS8 4083/4885 |
| US-20040198762-A1 | Deuterated rapamycin compounds, method and uses thereof | MALT1, MTOR, RICTOR | IGF2R 2141/4885GAA 2903/4885LGALS8 3626/4885 |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | IGF2R 38/4885GAA 987/4885LGALS8 680/4885 |
| US-20210198339-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | GPR119, INSR, IGF1R | IGF2R 38/4885GAA 987/4885LGALS8 680/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | IGF2R 29/4885GAA 4062/4885LGALS8 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.